«123456»Seite
6 articles, page 6 of 6

cme

The Treatment of Patients With HIV

Dtsch Arztebl Int 2010; 107(28-29): 507-16; DOI: 10.3238/arztebl.2010.0507

Vogel, M; Schwarze-Zander, C; Wasmuth, J; Spengler, U; Sauerbruch, T; Rockstroh, J K

Medizinische Klinik und Poliklinik I, Universitätsklinikum Bonn: Dr. med. Vogel, Dr. med. Schwarze-Zander, PD Dr. med. Wasmuth, Prof. Dr. med. Sprengler, Prof. Dr. med. Sauerbruch, Prof. Dr. med. Rockstroh

Background: Infection with the human immunodeficiency virus (HIV) remains a major medical challenge.

Methods: Selective literature review, including the current German/Austrian, European, and American guidelines on the treatment of HIV infection in adults.

Results: In Germany, 3000 persons become infected with HIV each year; in 2009, 67 000 persons in Germany were living with HIV. When highly active antiretroviral therapy (HAART) is initiated in time, patients can achieve a nearly normal life expectancy. Nonetheless, in Germany as elsewhere, 30% of patients receive the diagnosis of HIV infection only when they have reached the AIDS stage of the disease or are suffering from advanced immunodeficiency. HAART should be started, at the latest, when the CD4-positive helper cell count drops below 350/µL. Primary drug resistances, accompanying illnesses, and the patient’s living circumstances must all be taken into account in the selection of antiretroviral drugs. The goal of treatment is lasting suppression of HIV-RNA to below 50 copies per milliliter of plasma.

Conclusions: HIV testing should be offered to all patients at high risk for HIV infection and all persons newly diagnosed with a sexually transmitted disease. As persons with HIV grow older, their treatment is complicated by increasing comorbidity and requires increased vigilance for possible drug interactions. 

The first cases of acquired immunodeficiency syndrome (AIDS) appeared in the USA in the 1980’s, and the disease was soon determined to be due to a newly discovered virus, which was named “human immunodeficiency virus” (HIV). Since then, this infectious disease has spread around the world, with an estimated 33 million persons living with HIV worldwide in 2008 (e1e4). In Germany, about 67 000 persons were living with HIV in 2009. The annual number of new cases of HIV infection in Germany was on the rise from 2000 onward but has, fortunately, restabilized since 2007 at about 3000 per year (1).

In 1996, ten years after the discovery of HIV, the concept of treating HIV infection with highly active antiretroviral treatment (HAART) was introduced (e5). In HAART, a combination of antiretroviral drugs is used to bring about lasting suppression of HIV replication and thereby prevent the consequences of uncontrolled HIV infection—in particular, the loss of CD4-cell-mediated immunity. Theoretical considerations, as well as the clinical experience to date, suggest that HAART can be a successful method of lifelong treatment for some patients. According to mathematical models, patients’ life expectancy may become nearly normal if antiretroviral therapy is started in the early stage of HIV infection (stage A). For example, a 25-year-old, HIV-positive man who is not a drug abuser and starts receiving HAART today has a projected life span of 77.7 years; if he were HIV-negative, his projected life span would be 78.1 years (2). If HAART is started later on, however, life expectancies are much shorter. In another study, the projected life span of a 20-year-old HIV-positive man was determined to be 70 years if the helper cell count was over 200/µL at the start of HAART, but only 62 years for counts between 100/µL and 199/µL, and 52 years for a count under 100/µL (3). Despite the availability of effective treatment, and despite many public education campaigns, HIV infection is still often diagnosed too late, sometimes with drastic consequences: some patients, for example, already have AIDS by the time they are found to be HIV-positive (1). Persons at elevated risk for HIV infection should, therefore, be routinely offered HIV testing. Knowing about HIV-associated conditions can help physicians diagnose HIV early and initiate HAART in timely fashion.

Methods

In this article, we present current aspects of the epidemiology and treatment of HIV infection in the light of a selective review of the literature, including the German/Austrian, European, and American guidelines. The relevant literature was retrieved by a search on the terms “HIV guidelines” “ART guidelines”, and “HAARTguidelines.”

Learning objectives

This article should enable the reader to

  • become acquainted with the epidemiology of HIV infection,
  • know its natural course,
  • and understand the main features of its treatment.

The early detection of HIV infection

It is thought that half of all cases of HIV infection in Germany are detected too late, i.e., after the time that retroviral treatment should have been initiated (1). One-third of all patients already have an AIDS-defining disease, or advanced immunodeficiency with a CD4 cell count under 200/µL, at the time of diagnosis. For patients with undiagnosed HIV infection, there is a real, but incalculable, risk of serious adverse consequences until HIV is diagnosed. Early diagnosis is also good for the population at large, as appropriate steps taken thereafter can markedly lessen the spread of HIV to other persons (4). These steps include:

  • protected sexual intercourse,
  • the use of single-use needles and other equipment,
  • and effective treatment of HIV infection.

In Germany, HIV infection is most likely to be diagnosed late in older persons without any known or ascertainable risk of transmission who are immigrants from countries with a high prevalence of HIV, or who are of homosexual orientation (1). HIV is often diagnosed in such persons only after one or more earlier contacts with physicians in which the diagnosis was missed. In a recent study of persons in South Carolina (USA) whose HIV infection was diagnosed late, it was found that just under 20% of them had previously had clinical manifestations that might have aroused suspicion of HIV infection (5).

Classic AIDS-defining illnesses such as Pneumocystis jirovecii pneumonia (PCP), cerebral toxoplasmosis, and Kaposi’s sarcoma, are now well known (Box 1 gif ppt, Figure jpg ppt). There are other HIV-associated conditions, however, that should lead to the offering of an HIV test, including herpes zoster, oral hairy leukoplakia, oral thrush, and sexually transmitted diseases of any type (Boxes 1 and 2 gif ppt). In Germany, as in some other countries, an HIV test can be performed only with the patient’s consent (6).

The initiation of treatment

The best time to begin treatment remains unknown. The medical societies’ frequently updated recommendations reflect, on the one hand, the improving side effect profiles and ease of administration of HIV drugs, and, on the other hand, a new appreciation of the dangers of uncontrolled HIV infection, even if the helper cell count is high. Thus, the recommendations issued in recent years have tended to push the start of treatment earlier and earlier (Table 1 gif ppt). There is a consensus that all patients with HIV infection in CDC categories B and C (see Box 1) should be treated, regardless of their viral titers and CD4 cell counts (CDC, the US government's Centers for Disease Control and Prevention).

Even when the CD4 cell count is over 200/µL, in which case the risk of AIDS or another HIV-associated disease is low, uncontrolled HIV infection still poses a risk to health. In one study, patients whose HAART was begun earlier (when the CD4 cell count was above 350/µL) were less likely to have a myocardial infarction than those whose HAART was begun later (below 250/ µL) (9 cases versus 0 cases, with a combined hazard ratio of 7.0 for all non-AIDS-associated diseases) (7). The prognosis of chronic hepatitis C infection is significantly worsened by concurrent HIV infection, but HAART significantly lowers mortality and slows the progression of hepatic fibrosis (8). Several studies have shown that well-preserved immune function with a high helper cell count is associated with slower progression of hepatic fibrosis (9); thus, the early initiation of HAART is generally recommended to all patients who are co-infected with HIV and a hepatitis virus. Furthermore, recent data from the field of cancer epidemiology show that the risk of developing certain kinds of cancer already begins to rise when the CD4 cell count falls below 500/µL (10).

There is no consensus about the proper time to begin antiretroviral treatment in patients whose CD4 cell count exceeds 350/µL. Some American experts go so far as to recommend treatment to every HIV-positive patient (11), but European (12), including German (13), experts are more conservative and do not recommend treating patients whose CD4 cell count is above 350/µL, except under special circumstances (Table 1). On the other hand, the guidelines have become increasingly individualized, i.e., earlier initiation of treatment is now recommended for high-risk patients who have certain accompanying illnesses or a greater likelihood of progression of HIV disease (e.g., hepatitis co-infection, advanced age).

Therapeutic trials for acute HIV infection have yielded conflicting results to date; thus, for the time being, treatment in such cases should be given only in the setting of a controlled trial. As the treatment of HIV infection is a rapidly changing field, we recommend that treatment should be sought at specialized centers (medical practices or university outpatient clinics specializing in HIV treatment; cf. www.dagnae.de or www.daignet.de for centers in Germany).

The goal of treatment

The treatment of HIV poses a special challenge, as the virus replicates very rapidly (an estimated 1010 virus particles, or more, are produced daily) and mutates frequently (ca. 1 new mutation per replication cycle), without any major loss of function of most of its constituent proteins. HIV treatment can succeed over the long term only through lasting, maximal suppression of the viral burden, which not only limits viral replication, but also prevents the development of resistance to the antiviral drugs that are used. Experience has shown that lasting suppression of HIV-RNA below the detection threshold of currently used quantitative tests (20 to 50 copies/mL) is adequate for this purpose (13, 15).

Inadequate control of the viral burden (i.e., an HIV-RNA titer that does not drop below 400 copies/mL) raises the likelihood of selection of drug-resistant mutant viruses that can impair the success of treatment in the intermediate term (16). Patient compliance is also very important for long-term therapeutic success. Fewer than 5% of patients who begin HAART sustain a virological failure of treatment in the first year. Regular and continuous taking of HAART can effectively prevent the development of resistance. Forgetting to take tablets more than twice in one month elevates the risk of virological treatment failure by a factor of 2.8, in comparison to patients who never forget to take their medicine (14). Thus, therapeutic success is promoted by a physician-patient relationship founded on mutual trust, with extensive patient education about the nature and properties of the drugs to be taken, their specific side-effect profile, and the results than can be expected from them. Once the physician and the well-informed patient have made a joint decision to proceed to antiretroviral treatment, the goal should be maximal suppression of HIV replication, as this is the decisive criterion for long-term success.

The choice of antiretroviral drugs

As resistance develops rapidly when a single drug is given (monotherapy), antiretroviral drugs are usually given in combination. The drugs to be used should be chosen on the basis of the patient’s particular occupational and social characteristics, and any accompanying illnesses. As a rule, the recommended type of drug combination for patients who have not yet been treated for HIV consists of two nucleosidal (nucleotidal) reverse transcriptase inhibitors (N(t)RTI), together with a non-nucleosidal reverse transcriptase inhibitor (NNRTI), a protease inhibitor (PI) boosted with ritonavir, or an integrase inhibitor (INI). The main combinations that are currently recommended by the German and Austrian AIDS societies for antiretroviral treatment in previously untreated adults are listed in Table 2 (gif ppt).

The initiation of antiretroviral treatment should always be preceded by genotypic HIV resistance testing for the detection of primary drug resistance. Primary resistance is widespread in Germany, as elsewhere: in 2005, for example, 9% of all newly diagnosed cases of HIV infection in the federal state of North Rhine–Westphalia were found to have at least one viral mutation that was associated with resistance to an antiretroviral drug (17).

Any concurrent illnesses and, for women of child-bearing age, the patient’s desire to have children must be taken into account when antiretroviral drugs are chosen. Efavirenz should not be given to women who want to have children, as it is associated with embryonal neural tube defects (23). Physicians should also exercise special caution when giving efavirenz to mentally ill patients, as this drug is more likely to cause psychiatric complications in this patient group (19). Nevirapine is an NNRTI that can be used as an alternative to efavirenz, but it is more likely to cause strong cutaneous allergic reactions and hepatotoxicity in patients with relatively high CD4 counts. Thus, its use is recommended only for women with a CD4 count below 250/µL and men with a CD4 count below 400/µL.

When HAART is begun in a patient with chronic hepatitis, liver function tests should be performed frequently, as the transaminases may rise. If chronic hepatitis B infection is present, the indication for treating hepatitis B should be considered. If a highly replicative HBV infection (> 2000 IU/mL) with elevated transaminases is present, or if there is advanced hepatic fibrosis, the antiretroviral drugs that are used should also be antiviral inhibitors of HBV polymerase (e.g., tenofovir combined with emtricitabine or lamivudine). Patients with chronic hepatitis C infection for whom pegylated interferon/ribavirin treatment is planned should not be given didanosine, stavudine, or zidovudine, as these drugs exhibit enhanced toxicity when given together with ribavirin.

N(t)RTI doses may need to be adjusted in the presence of renal insufficiency, as these drugs are mainly eliminated by the renal route. Any other medications that the patient is taking should be meticulously checked for possible interactions with antiviral drugs. NNRTI and PI are mainly metabolized by the cytochrome P450 system, and this can have major implications both for HAART and for other medications that are taken at the same time. Thus, depending on the particular antiretroviral drug combination taken by the patient, the concomitant use of (for example) ergotamine, statins, proton-pump inhibitors, antihypertensive or antiarrhythmic medications, or even St. John’s wort can produce drug levels that are either subtherapeutic (lack of antiviral efficacy, increased risk of drug resistance) or toxic. Proton-pump inhibitors (PPI) can alter the solubility of antiretroviral drugs, e.g., atazanavir, with clinically relevant effects. Possible drug interactions can now be checked through a variety of Internet-based services (see www.ifi-interaktions-hotline.de or www.hiv-druginteractions.org) (20, 21).

Treatment monitoring

A first evaluation of the response to HAART should be performed four weeks after it is initiated. By this time, the HIV titer should have diminished by a factor of at least 100; if not, drug resistance, inadequate drug absorption, or poor compliance should be suspected. If the viral titer shows a favorable response when first checked, then it can be rechecked every three months thereafter. Effective treatment should suppress the viral titer below the threshold of detection (<50 copies/mL) within six months of the initiation of HAART.

Patients whose immune function is very rapidly reconstituted by HAART, or whose CD4 helper cell count was very low (below 50/ µL) when HAART was initiated, are at risk for the development of immune reconstitution inflammatory syndrome (IRIS). This paradoxical condition is characterized by the worsening of a previously unrecognized underlying disease, or by the new clinical manifestation of an opportunistic infection, even though the helper cell count is higher than before. IRIS is thought to reflect an excessive immune response to an overt or subclinical antigenic stimulus (“overshoot”) on the part of an immune system that has just regained its ability to respond. Thus, for example, in a patient with concomitant hepatitis C infection, the transaminases may rise after HAART is begun; or, in a patient with asymptomatic HIV infection, but a low CD4 cell count, tuberculosis may become clinically overt only after the CD4 count has been raised by HAART.

Changes and interruptions of HAART

The antiviral regimen may need to be changed if it is ineffective, if side effects arise, or if new drugs become available that are more effective, better tolerated, or easier to administer.

In virological treatment failure, the plasma virus load may be initially suppressed below the detection threshold of 50 copies/mL, as desired, only to rise above this threshold again multiple times. HAART should then be changed to include as many retroviral drugs as possible that are (still) effective against HIV in the individual patient; these drugs should be chosen on the basis of genotypic HIV resistance testing. Moreover, poor compliance should be considered as a possible differential diagnosis of virological treatment failure. An attempt should be made to improve compliance, if this is the underlying problem.

In Europe, fewer than 10% of all changes in HAART regimen are occasioned by virological treatment failure, while more than half are attributable to drug side effects and to the patients’ wishes (22). As patient compliance with continuous HAART is the main prerequisite for successful treatment, the patients’ complaints and wishes must always be carefully considered. Side effects and special circumstances will sometimes make interruptions in treatment unavoidable. If such events can be foreseen for an individual patient, then the choice of antiretroviral drugs should take these drugs’ different half-lives into account to avoid the functional equivalent of monotherapy with a high risk of drug resistance (NNRTIs).

Over the course of HAART, many patients feel the desire to take a holiday from treatment. One concept that has been proposed involves basing HAART on the CD4 count: if the count exceeds 350/µL, the treatment is paused; if and when the count drops below 250/µL again, the treatment is restarted. Multiple studies have shown, however, that the CD4 cells “won” by HAART generally fall back again to the previous nadir within a short time. Recently, a large-scale international trial of treatment based on the CD4 count had to be prematurely terminated, because significantly more AIDS-defining events, non-AIDS-defining events (cardiovascular, renal, and hepatic), and deaths were observed in patients in the CD4-based arm of the trial than in the patients who took HAART continuously regardless of their CD4 count (23). Thus, deliberately interrupting HAART is risky and generally not recommended.

Main conclusions for clinical practice

Very effective treatment for HIV infection is now available in Western industrialized countries. The proper time to begin antiretroviral combination therapy should be determined individually on the basis of the patient’s HIV-RNA concentration and CD4 cell count (surrogate markers), clinical stage of HIV infection, personal characteristics, and accompanying illnesses, if any. All such treatments should be preceded by genotypic HIV resistance testing to rule out primary resistance. The treatment of HIV infection is a complex matter; thus, consultative advice from a specialized HIV treatment center with the appropriate experience is always indicated.

Conflict of interest statement

Dr. Vogel has received lecture honoraria and financial support for travel to scientific meetings from Abbott, Tibotec, Gilead, BMS, ViiV Healthcare, Roche, Boehringer-Ingelheim, and Merck.

Dr. Schwarze-Zander has received lecture honoraria and financial support for scientific meetings and travel from Roche, Gilead, BMS, ViiV Healthcare, Pfizer, and Abbott.

Prof. Rockstroh has received lecture honoraria, financial support for travel to scientific meetings, and payment for service on advisory boards from Abbott, Tibotec, Gilead, BMS, ViiV Healthcare, Roche, Boehringer-Ingelheim, and MSD.

Prof. Sprengler has received payment for service on advisory boards from Gilead, BMS, Roche, and Novartis.

PD Wasmuth has received lecture honoraria, payment for service on advisory boards, research support, and reimbursement of travel expenses from Abbott, BMS, Pfizer, ViiV Healthcare, Roche, and Gilead.

Prof. Sauerbruch states that he has no conflict of interest as defined by the guidelines of the International Committee of Medical Journal Editors.

Manuscript submitted on 22 March 2010, accepted after revision on 15 June 2010.

Translated from the original German by Ethan Taub, M.D.

Corresponding author
Prof. Dr. med. Jürgen K. Rockstroh
Medizinische Klinik und Poliklinik I
Sigmund-Freud-Str. 25
53105 Bonn
juergen.rockstroh@ukb.uni-bonn.de

@For eReferences please refer to:
www.aerzteblatt-international.de/ref2810

Case Illustration available at:
www.aerzteblatt-international.de/10m0507

1.
Marcus-U, Fachgruppe 34 für HIV/AIDS u. a. sexuell oder durch Blut übertragbare Infektionen: Zum Verlauf der HIV-Epidemie in Deutschland bis Ende 2009. Epidemiologisches Bulletin 2009(48): 491–8.
2.
van Sighem A, Gras L, Reiss P, Brinkman K, de Wolf F: Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals. AIDS May 12. 2010; 24(10):1527–35.
3.
Antiretroviral Therapy Cohort Collaboration (ART-CC) writing committee: Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008; 37: 293–9.
4.
Quinn TC, Wawer MJ, Sewankambo N, et al.: Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000; 342(13): 921–9.
5.
Duffus WA, Weis K, Kettinger L, Stephens T, Albrecht H, Gibson JJ: Risk-based HIV testing in South Carolina health care settings failed to identify the majority of infected individuals. AIDS Patient Care STDS 2009; 23(5): 339–45.
6.
LG Köln, 08–02–1995 – 25 O 308/92: Schmerzensgeld wegen
HIV-Test ohne Einwilligung. NJW 1995: 1621, 2.
7.
Emery S, Neuhaus JA, Phillips AN, et al.: Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis 2008, 197(8): 1133–44.
8.
Qurishi N, Kreuzberg C, Luchters G, et al.: Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 2003; 362 (9397): 1708–13.
9.
Martin-Carbonero L, Benhamou Y, Puoti M, et al.: Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study. Clin Infect Dis 2004; 38(1): 128–33.
10.
Guiguet M, Boue F, Cadranel J, Lang JM, Rosenthal E, Costagliola D: Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Lancet Oncol 2009 10(12): 1152–9.
11.
Panel on Antiretroviral Guidelines for Adults and Adolescents.
Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services 2009: 1–161. Abrufbar unter: www.aidsinfo.nih.gov/ContentFiles/Adultand
AdolescentGL.pdf.
12.
Clumeck N, Dedes N, Pozniak A, Raffi F, EACS Executive Committee: Clinical Management and Treatment of HIV infected adults in
Europe. European AIDS Clinical Society 2009:5–23. Abrufbar unter: www.europeanaidsclinicalsociety.org/guidelinespdf/1_Treatment_ of_HIV_Infected_Adults.pdf.
13.
Deutsch-Österreichische AIDS-Gesellschaft. Leitlinien zur antiretroviralen Therapie im Erwachsenenalter. Stand März 2010. Abrufbar unter: www.daignet.de/site-content/hiv-therapie/leitlinien-1.
14.
Ballif M, Ledergerber B, Battegay M, et al.: Impact of previous virological treatment failures and adherence on the outcome of antiretroviral therapy in 2007. PLoS One 2009; 4(12): e8275.
15.
Aldous JL, Haubrich RH: Defining treatment failure in resource-rich settings. Curr Opin HIV AIDS 2009 Nov; 4(6): 459–66.
16.
de Mendoza C, Soriano V, Perez-Olmeda M, Rodes B, Casas E, Gonzalez-Lahoz J: Different outcomes in patients achieving complete or partial viral load suppression on antiretroviral therapy. J Hum Virol 1999; 2: 344–9.
17.
Sagir A, Oette M, Kaiser R, et al.: Trends of prevalence of primary HIV drug resistance in Germany. J Antimicrob Chemother 2007; 60: 843–8.
18.
De Santis M, Carducci B, De Santis L, Cavaliere AF, Straface G: Periconceptional exposure to efavirenz and neural tube defects. Arch Intern Med 2002 Feb 11; 162(3): 355.
19.
Bristol-Myers Squibb. Fachinformation Efavirenz. Berlin, 2009.
20.
Infektionsmedizinisches Institut Hamburg (ifi): Interaktions-Hotline. Abrufbar unter: www.ifi-interaktions-hotline.de
21.
The University of Liverpool: HIV Druginteractions. Abrufbar unter: www.hiv-druginteractions.org
22.
Mocroft A, Phillips AN, Soriano V, et al.: Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: increased incidence of stopping due to toxicity or patient/physician choice in patients with hepatitis C coinfection. AIDS Res Hum Retroviruses 2005 Sep; 21(9): 743–52.
23.
El-Sadr WM, Lundgren JD, Neaton JD, et al.: CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355(22): 2283–96.
24.
1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992 Dec 18; 41(RR-17): 1–19.
e1.
Gottlieb MS, Schroff R, Schanker HM, et al:. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. N Engl J Med 1981; 305(24): 1425–31.
e2.
Barre-Sinoussi F, Chermann JC, Rey F, et al.: Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983; 220(4599): 868–71.
e3.
Gallo RC, Sarin PS, Gelmann EP, et al.: Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS). Science 1983; 220(4599): 865–7.
e4.
Joint United Nations Programme on HIV/AIDS and World Health Organization. AIDS epidemic update: November 2009. Geneva, Switzerland: UNAIDS, 2009.
e5.
Gulick RM, Mellors JW, Havlir D, et al.: Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997; 337: 734–9.